Home > Boards > Free Zone > User's Groups > BOTTOM PLAYERS

PVCT = momentum with more on the way.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Caradoc Member Profile
Member Level 
Followed By 6
Posts 667
Boards Moderated 0
Alias Born 06/13/00
160x600 placeholder
Concerns About High U.S. Inflation May Be Overblown; Hawkish Talk by Two Federal Reserve Governors
Good day. Inflation next year could be much less than the 5.4% rate at which the consumer-price index has risen over the past 12 months, says Mark Hulbert, a contributor to sister publication Barron's. It's a rosy projection that comes from inflation models with the best historical track records, according to a new study, he writes. Meanwhile, The Wall Street Journal's Michael S. Derby writes that two Federal Reserve governors have indicated the Fed could move forward its timing for an interest-rate increase if inflation doesn't start moderating relatively soon. That aggressive talk on rates contrasts with the views of most other central bank officials, including Chairman Jerome Powell.
GlaxoSmithKline 3Q Net Profit Fell Slightly But Beat Expectations; Raises 2021 Adjusted EPS View -- Update
UK Treasury Chief Sets New Tax, Spending Plans
Norfolk Southern 3Q Earnings Rise
Icahn Launches $75/Share Tender Offer for Southwest Gas
Bio-Path Shares Up Premarket After FDA Trial Clearance
Hertz, Uber Partner to Add Up to 50,000 Teslas to Uber Network by 2023
General Dynamics 3Q Revenue Rises on Higher Aerospace, Marine Sales
Kraft Heinz Raises 2021 Outlook
Novatek 3Q Net Profit Rose Significantly
GlaxoSmithKline 3Q Net Profit Fell Slightly; Raises 2021 Adjusted EPS View
European Companies Anticipate Supply Chain Issues Will Stretch Into 2022
Bristol Myers Squibb Narrows Full-Year Earnings Guidance
Bristol-Myers Squibb Posts 3Q Sales Growth as R&D Spending Rises
Kraft Heinz 3Q Profit Rises; Company Deals With Inflationary Pressures
Santander Is Expected to Release Part of Its Pandemic-Related Provisions in 4Q
Top Company News of the Day
McDonald's Quarterly Sales, Earnings Surpass Street Views
Boston Scientific Tweaks Full-Year Guidance to Narrow Range
Boston Scientific Swings to 3Q Profit; Sales Grow
BASF Raises Guidance After Weathering Supply Bottlenecks in 3Q -- Update
TE Connectivity Sees Higher 1Q Revenue, Profit But Shy of Wall Street Views
Thermo Fisher Raises 2021 Sales, Earnings Guidance
Thermo Fisher 3Q Sales Grow With Boost From Covid-19 Response.
TE Connectivity 4Q Profit Surges Despite Global Supply Issues
Caradoc Member Level  Tuesday, 05/09/06 01:17:46 AM
Re: None
Post # of 2816 
PVCT = momentum with more on the way. A cancer cure at 2 bucks or so per share may sound fishy, and it sure sounded that way to me when I first heard about it last Thursday as it broke past $1.80 per share. Since then, I've done a lot of reading.

Just to get your DD started....

* Preliminary results are in for Phase 1 on breast cancer (kills cancer cells and doesn't enter or harm healthy cells) and Phase 1 on prostate cancer is about to start.
http://biz.yahoo.com/prnews/060427/sfth054.html?.v=51
and click on "initial report" at http://www.jmdutton.com/research/PVCT/index.html

* Schedule shows use of FDA's "fast track" approval process with combined Phase 2/ Phase 3 for breast cancer taking about 6 months.
http://www.knoxnews.com/kns/business/article/0,1406,KNS_376_4541948,00.html

* Throw in OS of 35.5 million and float of 21.3 million.
http://finance.yahoo.com/q/ks?s=PVCT.OB
and the CEO's personal effort to publicize the company as an investment opportunity between now and June 3,2006.
http://biz.yahoo.com/prnews/060503/nyw043.html?.v=53

My crystal ball sees real momentum for the next few days. Then, unlike the usual 3-day wonder, a 10-bagger before beginning Phase 4 for breast cancer. And after that, the numbers get big.

Caradoc


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences